RESUMO
It's universally well known that breastfeeding, due to its numerous beneficial effects on child and maternal health, is the best feeding method for infants. The use of medication by the nursing mother and the physician's advice to stop nursing are the most common reasons for the cessation of breastfeeding. The physician plays an extremely delicate role and should be able to assess risks and benefits for both mother and child. The issue of which drugs are safe to take during lactation is quite complicated. Three main factors must be taken into account: pharmacokinetics, assessment of the risk to the infant and to the lactation. Excellent sources of reliable information are the reference books. For the most up-to-date information it would be useful to consult the online medical literature. Few drugs have been demonstrated to be absolutely contraindicated during breastfeeding. Clear, safe and reliable information is still lacking for most drugs. It would be desirable to see an improvement in knowledge about mechanisms for transfer of drugs into milk, to analyze the biotransformation process for a given drug and to study the clinical consequences of infant exposure to drugs present in milk.
Assuntos
Aleitamento Materno , Educação de Pacientes como Assunto , Preparações Farmacêuticas , Aleitamento Materno/efeitos adversos , Aleitamento Materno/métodos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Feminino , Guias como Assunto , Humanos , Recém-Nascido , Lactação/efeitos dos fármacos , Lactação/metabolismo , Lactação/fisiologia , Leite Humano/química , Leite Humano/fisiologia , Farmacocinética , Prática Profissional/normasRESUMO
Oral mucositis (OM) is a common side effect experienced during haematopoietic SCT (HSCT), and it can have a significant impact on the quality of life of patients. A descriptive nurse-led study was undertaken in 19-member centres of the Italian national transplant group (GITMO) evaluating incidence, severity and duration of OM in patients undergoing HSCT. Data from 1841 patients between 2002 and 2006 was analyzed. Initial medical history and oral cavity assessment was performed. Assessment was repeated on the day of transplant, then daily, using the WHO (World Health Organisation) oral toxicity scale. A total of 71% of the patients evaluated developed mucositis and 21.6% developed severe mucositis. Duration of OM in most cases lasted for 10-14 days and resolved along with marrow reconstitution. Oral mucostitis is a frequent side effect in patients undergoing HSCT. The onset of severe mucositis seems to be related to the conditioning regimen used. This database provides a descriptive overview of the incidence and severity of mucositis and has encouraged participating centres to adopt routine evaluation and measurement of the oral cavity. The assessment tools are still used in some centres, providing a basis for further collaborative research projects.